Nashville, Tennessee
Phase 3 cancer trials in Nashville, TN
86 Phase 3 cancer studies are recruiting participants at sites in Nashville as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 86 studies are recruiting at a site in Nashville.
- By phase: Phase 2/3 (10), Phase 3 (76).
- By sponsor: industry (76), university, hospital or other (9), government (1).
- By research area: Lung Cancer (25), Breast Cancer (20), Lymphoma (15), Prostate Cancer (12), Melanoma (8), Pancreatic Cancer (6).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Nashville
Basic details from each study's public record (the 30 most recently updated of 86). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- One Oncology - Tennessee Oncology ( Site 0098) · SCRI Oncology Partners ( Site 7000) · Tennessee Oncology ( Site 0111)
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
- Registry record
- NCT06966700 · updated
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07683754 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Tennessee Oncology, PLLC
- Registry record
- NCT06982521 · updated
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study sites
- Sarah Cannon Research Institute · Tennessee Oncology Elliston Place Plaza
- Registry record
- NCT07413939 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Lung cancer studies recruiting in Nashville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Study site
- Clinical Study Sites
- Registry record
- NCT06767514 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Elliston Place Medical Oncology & Hematology ( Site 0215)
- Registry record
- NCT06623422 · updated
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Mirati Therapeutics Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06875310 · updated
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Eikon Therapeutics
- Study site
- Tennessee Oncology
- Registry record
- NCT07365319 · updated
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT05920356 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study sites
- Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate · Tennessee Oncology - Nashville - St. Thomas West Clinic
- Registry record
- NCT06472245 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Tennessee Oncology
- Registry record
- NCT07100080 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06646276 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Tennessee Oncology, PLLC - Investigational Drug Services · Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic
- Registry record
- NCT07144280 · updated
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study sites
- SCRI Oncology Partners · Tennessee Oncology
- Registry record
- NCT07361497 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Nashville
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- BioNTech SE
- Study sites
- SCRI Oncology Partners · Tennessee Oncology
- Registry record
- NCT07365995 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06136624 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Melanoma studies recruiting in Nashville
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT07068074 · updated
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Sarah Cannon Research Institute (SCRI)
- Registry record
- NCT07804186 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study sites
- Sarah Cannon Research Institute (SCRI) Oncology Partners · Tennessee Oncology
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Lymphoma studies recruiting in Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- Vanderbilt-Ingram Cancer Center
- Registry record
- NCT05303519 · updated
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031)
- Registry record
- NCT06136559 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06717347 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT07634471 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05675410 · updated
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT06091254 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Nashville
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US039 · Investigative Site US060 · Investigative Site US070
- Registry record
- NCT07522073 · updated
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study sites
- Sarah Cannon Research Institute · Tennessee Oncology
- Registry record
- NCT07562152 · updated
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Vanderbilt-Ingram Cancer Center
- Registry record
- NCT07621718 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections